Insiders Aren’t Buying Pfizer Stock, and That Could Help
Pfizer stock hovers around the $26 level as insiders aren’t buying Pfizer stock. Analysts point to a patient, value-f...
This comparison outlines 2024 tax treatment differences between dividends from ETFs and mutual funds for informed decisions.
24,763 articlesPfizer stock hovers around the $26 level as insiders aren’t buying Pfizer stock. Analysts point to a patient, value-f...
Bond yields climbed this week, increasing borrowing costs for homebuyers and businesses while influencing stock marke...
If Klarna reveals its 2025 earnings trajectory, investors will look at growth, profitability, and risk factors more t...
CFOs say U.S. firms rode out oil-driven energy costs, but fears of ongoing inflation and a slower economy are rising....
Meta just made striking moves in AI infrastructure that could tilt demand in Nvidia's favor. This deep dive explains ...
When a stock slips, smart investors look past the temporary dip. Domino's remains a dominant player with growing digi...
CrowdStrike accelerates an acquisition push as Palo Alto Networks doubles down on platform strategy. Both leaders rep...
Amazon lays out a multi-year AI and infrastructure push with a roughly $200 billion capex plan for 2026. Investors we...
Young shoppers are driving a tangible-media surge, lifting vinyl and print book sales in the U.S. and U.K. while rede...
Eli Lilly stands at a pivotal moment for investors. With a massive market-cap and a growing GLP-1 portfolio, the ques...
As nephros (neph) 2025 earnings approach, investors weigh revenue growth, margins, and cash runway. This guide breaks...
Small-city air links under 100 miles power the U.S. travel map, but the economics are shifting. This article breaks d...